Compound Maduramicin Ammonium Premix Veterinary Grade API is a homogeneous admixture of maduramicin ammonium, CAS 84878-61-5, molecular formula C₄₇H₈₃NO₁₇, molecular weight 934.17 g/mol, with a pharmacopoeial-grade carrier matrix. The active entity is a monovalent polyether ionophore obtained by submerged fermentation of Actinomadura yumaense; its coccidiostatic mechanism involves disruption of transmembrane monovalent cation gradients in susceptible Eimeria life-cycle stages. The premix is standardized to a declared potency of 10% w/w maduramicin ammonium activity, with contract manufacturing potencies available from 1% to 20% w/w. The product is intended solely for further compounding into oral powders, granules, capsules, tablets, and final medicated feed premixes; the inclusion of injections and solutions in the product designation refers to the API’s solubility behavior in non-aqueous solvent systems and does not imply parenteral safety in horses, dogs, or other non-target mammals. As a Type A medicated article under 21 CFR 558.3, the premix is subject to current good manufacturing practice requirements in 21 CFR 211 and 21 CFR 225. The API is isolated as a crystalline ammonium salt; typical appearance is a white to off-white free-flowing powder with not more than 5.0% loss on drying by USP 731. The carrier system is selected from calcium carbonate, rice hulls, corn cob, or lactose; carrier identity and particle size distribution must be declared on the certificate of analysis because they determine dilution behavior in subsequent feed milling. A manufacturer’s specification commonly requires not less than 95% of the premix to pass a 150 μm sieve when tested according to USP 811. The product is not intended for direct oral administration without prior geometric dilution.

How Does the Ammonium Counterion Affect Blending Uniformity and Granulation Endpoint Determination?

The ammonium salt form is selected over the free acid because it yields a more stable crystalline lattice, lower hygroscopicity than the corresponding sodium salt, and consistent potency retention during high-shear blending. The free acid is practically insoluble in aqueous media at pH 6.0–7.5, while the ammonium salt exhibits limited aqueous dispersibility but dissolves readily in methanol, ethanol, dichloromethane, and dimethyl sulfoxide. This solubility profile is critical for wet granulation: when the premix is granulated with aqueous binders such as povidone K30 or hypromellose, less than 5% of the active dissolves, so the granulation endpoint is governed by carrier wetting rather than by drug activation. Formulators using alcohol-based granulation fluids must recover and destroy the solvent because maduramicin ammonium is carried into the distillate and can contaminate downstream batches. Loss on drying after granulation should not exceed 3.0% at 105 °C for 15 minutes when tested by USP 731, because residual moisture above this value accelerates agglomerate hardening and reduces tablet tensile strength. In broiler chicken and turkey feeds, the approved final feed concentration range is 5–6 g/ton, equivalent to 5–6 ppm, as listed for maduramicin ammonium in 21 CFR 558. This concentration is markedly lower than the corresponding ranges for monensin (90–120 ppm) and salinomycin (60 ppm), which imposes a strict geometric dilution sequence in feed mills. A typical sequence begins with a 10% w/w premix passed through a 10:1 carrier dilution to a 1% w/w intermediate, then a second 10:1 dilution to a 1000 ppm working premix, followed by a 200:1 final feed dilution. Mixers used for this sequence must achieve a coefficient of variation not greater than 5% for the active assay across 10 sampling points, as specified in ISO 6497 for animal feeding stuffs sampling. Ribbon blenders of 500–2000 kg working capacity and twin-shaft paddle mixers are preferred because the low inclusion rate requires shear without excessive fines generation. Segregation risks increase when the carrier and active particle size distributions differ by more than 50 μm in median diameter; therefore, pre-blending the API with a carrier of similar bulk density (0.45–0.65 g/cm³) is mandatory.

When Tablets or Capsules Are Compounded from the Premix, Which Excipient Boundaries Prevent Potency Drift and Dissolution Failure?

Direct compression of maduramicin ammonium premix into tablets is constrained by the low dose fraction of active per unit dose and the lubricant sensitivity of the active. In a 10% w/w premix, a 50 mg unit dose requires 500 mg of premix; therefore, tableting is typically limited to large-animal boluses or multi-gram oral dosage forms unless the API is first isolated or spray-dried onto a high-potency carrier. Microcrystalline cellulose and dibasic calcium phosphate dihydrate are compatible fillers, but magnesium stearate should not exceed 1.0% w/w because the hydrophobic lubricant film retards wetting of the sparingly soluble active. Strongly acidic excipients such as citric acid should be avoided because protonation of the carboxylate group converts the salt back to the poorly dispersible free acid and reduces assay recovery in aqueous extraction. For capsule filling, the premix may be filled directly into hard gelatin capsules if the angle of repose is below 40° and the flowability index meets USP 1174; otherwise, roller compaction with subsequent milling to granules passing a 600 μm screen is preferred. Published stability data for this specific configuration is limited; sponsors must therefore conduct VICH GL3 and VICH GL45 forced degradation studies before assigning a shelf life. The analytical determination of maduramicin ammonium in premixes and finished feeds is complicated by the absence of a strong UV chromophore in the polyether backbone. HPLC methods using UV detection at 210 nm suffer from matrix interference from cereal-based carriers and require extensive sample cleanup. Pharmacopoeial monographs for maduramicin ammonium commonly specify liquid chromatography with post-column derivatization using sulfuric acid and vanillin, which yields a chromophore for visible detection near 520 nm. For residue surveillance in edible tissues, liquid chromatography–tandem mass spectrometry in positive electrospray mode provides the required sensitivity down to 1 μg/kg in liver and muscle; published multi-residue methods also cover monensin, salinomycin, and narasin simultaneously. Assay acceptance for the premix is typically 95.0–105.0% of the declared potency, with relative standard deviation not more than 2.0% across six replicate injections. Forced degradation under 0.1 M hydrochloric acid at 60 °C for 24 hours demonstrates loss of the ionophore ring; however, the molecule is stable in neutral and alkaline aqueous conditions up to 40 °C for 6 months when protected from light.

Ionophore Selectivity and Cross-Contamination Barriers in Multi-Species Feed Facilities

Maduramicin ammonium differs from monensin, salinomycin, and narasin primarily in its use concentration and selectivity for monovalent cations. The approved broiler inclusion of 5–6 ppm for maduramicin ammonium contrasts with 90–120 ppm for monensin, 60 ppm for salinomycin, and 70 ppm for narasin; this 15- to 24-fold difference in use rate creates a disproportionate cross-contamination hazard. Horses are exquisitely sensitive to all polyether ionophores; published case reports describe fatal acute myocardial degeneration in horses following accidental ingestion of maduramicin-contaminated feed, although exact toxic thresholds are not fully characterized. Therefore, dedicated production lines or validated flush sequences with inert carriers are required before equine feed can be manufactured on the same equipment. The flush procedure typically uses 50–100 kg of ground corn per tonne of mixer capacity, repeated until the assay falls below the limit of detection of 0.1 ppm in the flushed carrier. Carryover into laying hen feed is also prohibited because maduramicin ammonium residues transfer into eggs; regulatory withdrawal periods and residue limits vary by jurisdiction but require adherence to the maximum residue limit established where applicable under Commission Regulation (EU) No 37/2010.

Ionophore	CAS RN	Molecular weight (g/mol)	Typical broiler feed concentration (ppm)	Species restriction boundary
Maduramicin ammonium	84878-61-5	934.17	5–6	Not for equine; not for laying hens
Monensin sodium	22373-78-0	692.86	90–120	Not for equine; observe withdrawal periods in cattle
Salinomycin sodium	55721-31-8	772.98	60	Not for equine; not for laying hens
Narasin	55134-13-9	765.04	70	Not for equine; not for laying hens

A marketing authorization application for a finished veterinary medicinal product containing maduramicin ammonium must include a complete chemistry, manufacturing, and controls dossier prepared under the Common Technical Document format. The active substance master file should specify the production strain, fermentation conditions, extraction and purification steps, and the salt formation procedure. Residual solvents must meet VICH GL18 limits; the fermentation-derived API typically requires testing for methanol, ethanol, and acetone at not more than 5000 ppm total, with individual limits aligned to ICH Q3C. The premix specification must include loss on drying not more than 5.0%, residue on ignition not more than 1.0%, and heavy metals not more than 20 ppm when tested by USP 231 or equivalent. Microbial limits for oral dosage forms require total aerobic microbial count not exceeding 10³ CFU/g and total combined yeasts and molds not exceeding 10² CFU/g, with absence of Escherichia coli and Salmonella in 10 g as per USP 62. Batch records must document the geometric dilution steps, mixer speed, blend time, and sampling plan to demonstrate homogeneity.

Regulatory Filing Requirements for Multi-Dosage Form Veterinary APIs

The product must be released against a certificate of analysis that includes identity, assay, loss on drying, residue on ignition, heavy metals, and microbial limits. For the European market, the premix falls under the definition of an intermediate product for veterinary medicinal use under Regulation (EU) 2019/6, Article 2(8), and must be manufactured in accordance with Part II of the EU GMP Guide for Active Substances. Stability data generated under VICH GL3 should cover at least 12 months at 25 °C/60% RH and 6 months at 40 °C/75% RH for the initial filing; bracketing or matrixing designs are acceptable when justified. The registered specification for the final medicated feed premix must include a potency assay with acceptance limits of 95.0–105.0% of declared maduramicin ammonium activity, and the feed mill must retain retained samples for not less than 1 year after final distribution.

Parameter	Standard / Method	Typical specification
Identity	USP 197K infrared absorption	Matches reference spectrum
Assay	HPLC with post-column derivatization	95.0–105.0%
Loss on drying	USP 731	≤ 5.0%
Residue on ignition	USP 281	≤ 1.0%
Heavy metals	USP 231	≤ 20 ppm
Microbial limits	USP 61 / USP 62	TAMC ≤ 10³ CFU/g; TYMC ≤ 10² CFU/g
Feed homogeneity	ISO 6497	CV ≤ 5%
Final feed concentration	21 CFR 558	5–6 g/ton

Storage of the premix requires tightly closed, light-resistant containers held at controlled room temperature 20–25 °C, with excursions permitted only between 15 °C and 30 °C. Under these conditions, the manufacturer’s assigned shelf life typically extends to 24 months. Re-test dates after container opening should be assigned based on moisture ingress; if relative humidity exceeds 60%, the product should be pre-dried at 40–50 °C before blending to prevent agglomeration and non-uniform potency. Waste and rinse fluids containing maduramicin ammonium must be inactivated by incineration or chemical oxidation; discharge into aquatic environments is prohibited because of the compound’s toxicity to freshwater invertebrates. The product is incompatible with strong acids, oxidizing agents, and amine-based additives in bulk storage.